论文部分内容阅读
本文最初发表于2016年的《Journal of Clinical Oncology》杂志上,文章题录为:Chang YJ,Xu LP,Wang Y,et al.Controlled,randomized,open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation[J].J Clin Oncol,2016,34:1855-1863。本研究证实在单倍型相合骨髓/外周血混合移植模式下,危险分层指导的小剂量激素预防不仅降低了移植后Ⅱ~Ⅳ度急性移植物抗宿主病发生率,而且促进了血小板重建,降低了激素相关的股骨头坏死和继发性高血压的发生率,使单倍型相合移植更安全。经通信作者允许,再次以佳文解读的形式来阐释这一发现。
This article was originally published in the Journal of Clinical Oncology 2016, titled: Chang YJ, Xu LP, Wang Y, et al. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft -versus-host disease after haploidentical transplantation [J]. J Clin Oncol, 2016, 34: 1855-1863. This study confirmed that haplotype combined with bone marrow / peripheral blood mixed transplantation mode, the risk of stratification guide small dose of hormone prevention not only reduces the incidence of acute graft-versus-host disease Ⅱ ~ Ⅳ after transplantation, but also promote platelet reconstruction, Reduce the hormone-related femoral head necrosis and the incidence of secondary hypertension, so that haploidentical transplantation more secure. With the permission of the author of the communication, this finding is again illustrated in the form of an article reading.